dibenz(b,f)(1,4)oxazepine-10(11h)-carboxylic acid, 8-chloro-, 2-acetylhydrazide has been researched along with Bright Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Liu, J; Qiu, Z; Xu, Y; Yin, J | 1 |
1 other study(ies) available for dibenz(b,f)(1,4)oxazepine-10(11h)-carboxylic acid, 8-chloro-, 2-acetylhydrazide and Bright Disease
| Article | Year |
|---|---|
Effect of selective inhibition or activation of PGE2 EP1 receptor on glomerulosclerosis.
Topics: Animals; Apoptosis; Cells, Cultured; Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide; Dinoprostone; Disease Models, Animal; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glomerulonephritis; Heat-Shock Proteins; Kidney; Male; Mesangial Cells; Mice; Mice, Inbred C57BL; Nephrectomy; Prostaglandin Antagonists; Receptors, Prostaglandin E, EP1 Subtype; Transforming Growth Factor beta1; TRPC Cation Channels | 2020 |